Symbols

PRDS(Delisted)

Pardes Biosciences·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PRDS

Pardes Biosciences, Inc.

A clinical-stage biopharmaceutical company that develops novel oral antiviral drug candidate for SARS-CoV-2 infections and COVID-19 disease

Industry

Established Date

08/21/2020

Listing Date

02/17/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.pardesbio.com

Security Type

Common stock

Office address

2173 Salk Avenue, Suite 250, PMB#052, Carlsbad, CA 92008

Business

Introduction

Pardes Biosciences, Inc., was incorporated in Delaware on August 21, 2020. Pardes Biosciences is a clinical-stage biopharmaceutical company that aims to help address the scale of the pandemic that began with COVID 19. They are applying modern reversible covalent chemistry as a starting point for the discovery and development of new oral drug candidates, while reimagining the patient's journey to obtain these drugs. The company's lead product candidate, PBI-0451, is being developed as a direct-acting oral antiviral drug for the treatment and prevention of SARS-CoV-2 infection, the virus that causes COV19.

Company Financials

EPS

PRDS has released its 2023 Q1 earnings. EPS was reported at -0.3, versus the expected -0.41, beating expectations. The chart below visualizes how PRDS has performed over recent quarters, highlighting trends in earnings surprises.